Publications
Stabell LA, Johnsen E, Kroken RA, Løberg EM, Blindheim A, Joa I, Reitan SK, Rettenbacher M, Munk-Jørgensen P, Gjestad R. Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial
Kroken RA, Johnsen E, Alisauskiene R, Anda LG, Bartz-Johannessen CA, Berle JØ, Bjarke J, Bruserud Ø, Fathian F, Fleischhacker WW, Hughdal K, Joa I, Kjelby E, Larsen TK, Løberg EM, Ratke I, Rettenbacher M, Sinkeviciute, Skrede S, Stabell L, Steen VM, Torsvik A, Reitan SMK. Cytokine changes during a 12-month pragmatic randomized trial in schizophrenia spectrum disorders comparing amisulpride, aripiprazole and olanzapine.
https://doi.org/10.1016/j.psychres.2026.117266
Askeland Buer A, Strømme MF, Schmid M, Fismen A-S, Gjestad R, Senneseth M. Frequent psychiatric admissions and the risk of suicide: a prospective total cohort study 2005-2023.
https://doi.org/10.1080/08039488.2025.2604656
Stabell LA, Johnsen E, Kroken RA, Loberg EM, Kjelby E, Joa I et al. Levels of and changes in psychosis symptoms and clinical insight: Exploring the impact of differential antipsychotic mechanisms. https://doi.org/10.1016/j.psychres.2026.116948
Fathian F, Divkovic I, Fagerbakke Stromme M, Mykletur A, Kroken RA, Bartz-Johannessen CA, Johnsen E. Natural-cause mortality and C-reactive protein levels in patients with schizophrenia: A prospective total cohort study.
https://doi.org/10.1016/j.bbih.2025.101133
Hoprekstad GE, Johnsen E, Bartz-Johannessen C, Bjarke JK, Drosos P, Fasmer OB, Gjerde KV, Reitan SK, Skrede S, Sommer IEC, Stbell L, Steen VM, Kroken RA. Prednisolone add-on in early phase schizophrenia: A randomized, double-blind, placebo-controlled pilot study.
https://doi.org/10.1016/j.bbih.2025.101047
Fernando MB, Fan Y, YZhang Y, Tokolyi A, Murphy AN, Kammourh S, Deans PJM, Ghorbani S, Onatzevitch R, Pero A, Padilla C, Williams SE, Flaherty EK, Prytkova IA, Cao L, Knowles DA, Fang G, Slesinger PA, Brennand KJ. Phenotypic complexities of rare heterozygous neurexin-1 deletions.
https://doi.org/10.1038/s41586-025-08864-9
Garcia MF, Retallick-Townsley K, Pruitt A, Davidson E, Balafkan N, Warrell J, Huang TC, Kibowen A, Chu Z, Dai Y, Fitzpatrick SE, Meng R, Sen A, Cohen S, Livoti O, Khan S, Becker C, E Silva ALT, Liu J, Dossou G, Cheung J, Liu S, Ghorbani S, Deans PJM, Ceciucis M, Emani P, Gao H, Shen H, Gerstein M, Wang Z, Huckins LM, Hoffman EJ, Brennand K. Dynamic convergence of neurodevelopmental disorder risk genes across neurodevelopment.
https://doi.org/10.1101/2024.08.23.609190
Ratke I, Torsvik A, Bartz-Johannessen CA, Fathian F, Joa I, Reitan SMK, Løberg EM, Rettenbacher M, Skrede S, Steen VM, Johnsen E, Kroken RA. Sex differences in the peripheral levels of cytokines during 12-month antipsychotic treatment in a drug-naive schizophrenia spectrum cohort. https://doi.org/10.1016/j.bbih.2025.100959
Rajen N, Velure HW, Johnsen E, Bjorke-Monsen AL. Impaired folate status in patients with mental disorders.
https://doi.org/10.1017/neu.2025.1
Strømme MF, Thue Augustsson M, Bartz-Johannessen C, Stautland A, Mykletun A, Kroken RA, Mehlum L, Kjelby E, Johnsen E. Suicidality and use of psychotropic medications in patient with schizophrenia: a prospective cohort study.
https://doi.org/10.1017/s0033291724002873